""

Merkel cell carcinoma

Recruiting after consultation
Open recruiting

Neoadjuvant Therapy

There are currently no studies available

Adjuvant Therapy

There are currently no studies available

Metastatic Disease: First-Line-Therapy

There are currently no studies available

Metastatic Disease: Follow-Up Treatment

Title: A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve
Phase: I/II
Contact: Silvia Koerner / Study Nurse
Clinical Investigator: Prof. Dr. Jessica Hassel
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03787602
EudraCT-Number: Siehe EU klinisches Studienregister 2020-002820-35

Surgical Study

There are currently no studies available

Radiotherapy Study

There are currently no studies available

Other study

There are currently no studies available